C

ombing through the data of its most recent setback in Alzheimer’s disease, Merck (MRK) sees a glimmer of hope that a once-failed drug might come through for patients in the earliest stages of disease.

Merck’s drug, verubecestat, was virtually indistinguishable from placebo in a trial involving roughly 2,000 patients with mild or moderate Alzheimer’s, the company revealed Thursday. Over 18 months, patients saw their cognition, function, and dementia grow worse regardless of whether they got  verubecestat or a sugar pill, and no matter whether their disease was mild or moderate. The results were so decisively negative that Merck ended the trial five months early.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.